Hologic (NASDAQ:HOLX) had its price target upped by equities research analysts at Morgan Stanley from $55.00 to $68.00 in a research note issued on Friday, BenzingaRatingsTable reports. The firm presently has an “equal weight” rating on the medical equipment provider’s stock. Morgan Stanley’s target price indicates a potential downside of 2.55% from the company’s current price.
Several other analysts also recently issued reports on the stock. SVB Leerink lifted their price target on shares of Hologic from $66.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday. BidaskClub upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Wednesday, June 24th. UBS Group lowered their target price on shares of Hologic from $58.00 to $52.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Citigroup lifted their price target on Hologic from $63.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. increased their price objective on Hologic from $45.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $65.38.
Shares of NASDAQ HOLX opened at $69.78 on Friday. The firm has a market capitalization of $18.07 billion, a P/E ratio of 28.25, a P/E/G ratio of 3.69 and a beta of 1.47. The firm’s 50-day moving average price is $57.42 and its 200-day moving average price is $50.06. The company has a current ratio of 1.47, a quick ratio of 1.04 and a debt-to-equity ratio of 1.22. Hologic has a 1-year low of $26.49 and a 1-year high of $70.35.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.37. The business had revenue of $822.90 million during the quarter, compared to analyst estimates of $622.96 million. Hologic had a return on equity of 31.40% and a net margin of 20.03%. The firm’s revenue was down 3.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 EPS. Equities research analysts forecast that Hologic will post 2.42 EPS for the current year.
In other Hologic news, insider Peter J. Valenti III sold 10,493 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $51.82, for a total value of $543,747.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 190,996 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $50.97, for a total value of $9,735,066.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 243,932 shares of company stock valued at $12,507,250. 1.00% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC raised its stake in Hologic by 141.4% in the second quarter. SG Americas Securities LLC now owns 78,026 shares of the medical equipment provider’s stock valued at $4,447,000 after purchasing an additional 45,699 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Hologic by 102.9% during the 2nd quarter. Exchange Traded Concepts LLC now owns 5,508 shares of the medical equipment provider’s stock worth $314,000 after acquiring an additional 2,794 shares during the last quarter. State Street Corp lifted its holdings in shares of Hologic by 1.2% during the 1st quarter. State Street Corp now owns 11,584,851 shares of the medical equipment provider’s stock worth $406,628,000 after acquiring an additional 137,837 shares during the last quarter. Alliancebernstein L.P. grew its position in Hologic by 1.7% in the first quarter. Alliancebernstein L.P. now owns 418,358 shares of the medical equipment provider’s stock worth $14,684,000 after acquiring an additional 7,087 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Hologic by 1.7% in the first quarter. The Manufacturers Life Insurance Company now owns 1,401,237 shares of the medical equipment provider’s stock valued at $49,183,000 after acquiring an additional 22,798 shares during the last quarter. 92.34% of the stock is owned by institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.